TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02201342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Udenafil
Description: Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Udenafil
Description: Drug
Study: NCT02107755

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiosurgery
Description: Undergo stereotactic radiosurgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Blood and tissue samples will be collected for research purposes.
Study: NCT01442181

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimally Invasive Surgery
Description: Small thumb sized incisions are made on each side of the chest wall where instruments are inserted for the purpose of completing the surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical therapy
Description: Patients are treated with rhythm and rate control medications.
Study: NCT02841488

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Perineural catheter
Study: NCT03283943

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Focal radiotherapy
Description: Focal sensitizing radiotherapy will be given at a starting dose level of 24 Gray (6 Gy X 4 fractions), and may be escalated to 32 Gy (8Gy X4 fractions).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500 mg IV every 28 days
Study: NCT04937348

Intervention type: DIAGNOSTIC_TEST
Intervention: Acquisition and analysis of milk samples
Description: In order to ensure reproducible results, breast milk samples were collected using a breast pump. Samples were taken in the morning, after the newborn was breastfed. The entire breast was emptied. In order to ensure the stability of the microbiological and nutritional composition, the milk samples were cooled immediately after collection, and then divided into test tubes and frozen (-80 C) until the laboratory tests were made.~The concentrations of macronutrients (protein, fat, carbohydrate) in breast milk were determined using a Human Milk Analyzer (HMA; Miris, Uppsala). Tissue hormones, e.g. adipokines: visfatin, omentin-1 were determined by ELISA method using commercial reagent kits.

Intervention type: DIAGNOSTIC_TEST
Intervention: Acquisition and analysis of milk samples
Description: In order to ensure reproducible results, breast milk samples were collected using a breast pump. Samples were taken in the morning, after the newborn was breastfed. The entire breast was emptied. In order to ensure the stability of the microbiological and nutritional composition, the milk samples were cooled immediately after collection, and then divided into test tubes and frozen (-80 C) until the laboratory tests were made.~The concentrations of macronutrients (protein, fat, carbohydrate) in breast milk were determined using a Human Milk Analyzer (HMA; Miris, Uppsala). Tissue hormones, e.g. adipokines: visfatin, omentin-1 were determined by ELISA method using commercial reagent kits.

Intervention type: DIAGNOSTIC_TEST
Intervention: Acquisition and analysis of milk samples
Description: In order to ensure reproducible results, breast milk samples were collected using a breast pump. Samples were taken in the morning, after the newborn was breastfed. The entire breast was emptied. In order to ensure the stability of the microbiological and nutritional composition, the milk samples were cooled immediately after collection, and then divided into test tubes and frozen (-80 C) until the laboratory tests were made.~The concentrations of macronutrients (protein, fat, carbohydrate) in breast milk were determined using a Human Milk Analyzer (HMA; Miris, Uppsala). Tissue hormones, e.g. adipokines: visfatin, omentin-1 were determined by ELISA method using commercial reagent kits.
Study: NCT00599131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 1. Day 1: 100 mg/m2, administered as an i.v. infusion will run over one hour. 2. Day #23: Subjects with a \< 50% response (NR) to induction chemotherapy will undergo salvage laryngectomy followed by RT. Cisplatin will be added to radiation for patients whose surgical pathology reveals high-risk features (i.e. extracapsular spread, \> 2 positive lymph nodes, perineural invasion, or positive margins). Cisplatin will either be dosed a 100 mg/m2 every 21 days or 40 mg/m2 weekly at the discretion of the prescribing physician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 1. Cetuximab will be administered at 400 mg/m2 on Day 20 (2 hour administration). 2. Cetuximab will be administered in combination with radiation therapy to those subjects who had a Partial or Complete response after the first cycle of the chemotherapy regimen is administered. The dosage for these administrations is 250 mg/m2 over sixty minutes and it will be administered for six weeks.
Study: NCT04937348

Intervention type: DIAGNOSTIC_TEST
Intervention: Collection, preparation and analysis of mother's blood samples.
Description: Blood samples were collected from the mothers (fasting if possible) on the day the milk samples were taken. After collection, fasting glucose and insulin, as well as glycated hemoglobin were marked, and the other samples were centrifuged and frozen until analyzed (-80 C). Determination of adipokines was performed by ELISA method, using commercial reagent kits.

Intervention type: DIAGNOSTIC_TEST
Intervention: Collection, preparation and analysis of mother's blood samples.
Description: Blood samples were collected from the mothers (fasting if possible) on the day the milk samples were taken. After collection, fasting glucose and insulin, as well as glycated hemoglobin were marked, and the other samples were centrifuged and frozen until analyzed (-80 C). Determination of adipokines was performed by ELISA method, using commercial reagent kits.

Intervention type: DIAGNOSTIC_TEST
Intervention: Collection, preparation and analysis of mother's blood samples.
Description: Blood samples were collected from the mothers (fasting if possible) on the day the milk samples were taken. After collection, fasting glucose and insulin, as well as glycated hemoglobin were marked, and the other samples were centrifuged and frozen until analyzed (-80 C). Determination of adipokines was performed by ELISA method, using commercial reagent kits.

Intervention type: DIAGNOSTIC_TEST
Intervention: Body composition assessment
Description: The body composition of newborns was determined by a non-invasive electrical bioimpedance method using the body composition analyzer.
Study: NCT04223609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: 5 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: 5 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oxycodone-matched placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oxycodone-matched placebo tablet

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EyeLink 1000 Plus
Description: Non-invasive video-based eye tracking system
Study: NCT04937348

Intervention type: DIAGNOSTIC_TEST
Intervention: Body composition assessment
Description: The body composition of newborns was determined by a non-invasive electrical bioimpedance method using the body composition analyzer.

Intervention type: DIAGNOSTIC_TEST
Intervention: Body composition assessment
Description: The body composition of newborns was determined by a non-invasive electrical bioimpedance method using the body composition analyzer.

Intervention type: OTHER
Intervention: Anthropometric measurements
Description: Based on the mother's medical records, maternal height and pregnancy weight changes were recorded. On the day the biological material is collected, the mother was weighed.~From the baby's documentation, measurements of the length, head circumference and body weight taken after delivery and during the hospitalization were recorded. These measurements were repeated on the days of the body composition analysis.

Intervention type: OTHER
Intervention: Anthropometric measurements
Description: Based on the mother's medical records, maternal height and pregnancy weight changes were recorded. On the day the biological material is collected, the mother was weighed.~From the baby's documentation, measurements of the length, head circumference and body weight taken after delivery and during the hospitalization were recorded. These measurements were repeated on the days of the body composition analysis.

Intervention type: OTHER
Intervention: Anthropometric measurements
Description: Based on the mother's medical records, maternal height and pregnancy weight changes were recorded. On the day the biological material is collected, the mother was weighed.~From the baby's documentation, measurements of the length, head circumference and body weight taken after delivery and during the hospitalization were recorded. These measurements were repeated on the days of the body composition analysis.
Study: NCT03952143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Degludec
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Degludec
Description: Administered SC
Study: NCT00824148

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guardian REAL-Time Continuous Glucose Monitoring System
Description: One group will use the glucose monitoring system for 1 month

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional self-monitoring of plasma glucose
Description: Finger prick blood glucose measurements
Study: NCT02609295

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1.2 g (two capsules) of medium-chain triglyceride (MCT) oil

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ALA group
Description: 1.2 g (two capsules) of perilla oil
Study: NCT00528606

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: collagenase clostridium histolyticum
Description: Subjects could have received up to three injections of AA4500 into the cord of the affected hand. Each injection was separated by at least 30 days. Individual cords may have received up to a maximum of three injections.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects could have received up to three injections of placebo into the cord of the affected hand. Each injection was separated by at least 30 days. Individual cords may have received up to a maximum of three injections.
Study: NCT00599131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-FU will be administered 750 mg/m2 in 0.9% normal saline as a 24-hour continuous infusion, days #1-4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2 by I.V. over one hour on Day # 1 only
Study: NCT01886326

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consumption of 42 grams of peanuts daily
Description: Consumption of the given 42 grams of peanuts daily without instructions for use (i.e. with/without meals, etc.)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consumption of 42 grams of peanuts daily
Description: Consumption of the given 42 grams of peanuts daily without instructions for use (i.e. with/without meals, etc.)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consumption of 42 grams of peanuts daily
Description: Consumption of the given 42 grams of peanuts daily without instructions for use (i.e. with/without meals, etc.)
Study: NCT04223609

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EyeLink 1000 Plus
Description: Non-invasive video-based eye tracking system

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Oculo-Cognitive Addition test (OCAT)
Description: Subject will have to look for numbers on a screen and add these numbers together. OCAT will be presented on a computer screen with attached eye tracking device at the bottom part.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Oculo-Cognitive Addition test (OCAT)
Description: Subject will have to look for numbers on a screen and add these numbers together. OCAT will be presented on a computer screen with attached eye tracking device at the bottom part.
Study: NCT02726581

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days, IV (intravenous)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days, IV (intravenous)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: Specified dose on specified days, IV
Study: NCT04223609

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VT3mini - Eye Tracking Technology for OEMs
Description: Non-invasive eye-tracking device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VT3mini - Eye Tracking Technology for OEMs
Description: Non-invasive eye-tracking device
Study: NCT00797420

Intervention type: DRUG
Group type: OTHER
Intervention: Fluconazole Loading Dose
Description: Single Fluconazole loading dose 25 mg/kg
Study: NCT02726581

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pomalidomide
Description: Specified dose on specified days, PO (by mouth)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Specified dose on specified days, PO (by mouth)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Specified dose on specified days, PO (by mouth)
Study: NCT00797420

Intervention type: DRUG
Group type: OTHER
Intervention: Fluconazole Loading Dose & High Dose
Description: Fluconazole loading dose 25 mg/kg, followed by fluconazole 12 mg/kg q24 hours for total of 5 days
Study: NCT02726581

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Specified dose on specified days, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Specified dose on specified days, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Specified dose on specified days, PO
Study: NCT02495857

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronate Injectable Viscosupplement
Description: Test product of a 1% sodium hyaluronate for injection

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Euflexxa IA injection
Description: Brand product of a 1% sodium hyaluronate for injection

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride, sterile
Study: NCT01833052

Intervention type: DEVICE
Group type: OTHER
Intervention: TAVI (Medtronic CoreValve)

Intervention type: DEVICE
Group type: OTHER
Intervention: TAVI (Medtronic CoreValve)

Intervention type: DEVICE
Group type: OTHER
Intervention: Claret-Filter
Study: NCT01352481

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Early parent-based speech intervention program
Description: Seven 1h sessions during a three-month period.
Study: NCT04795154

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga excercise
Description: Yoga exercise in pre-eclampsia \>20 weeks of pregnancy woman, treatment number was 4 times.
Study: NCT01629069

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness based Resilience Training
Description: 6 weekly group sessions
Study: NCT02616809

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maintaining posture and energy expenditure
Description: Participants will sit continuously for 8-hrs during a simulated office environment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Increasing energy expenditure
Description: Participants will cycle slowly while seated in prescribed hourly intervals. This condition will increase energy expenditure while keeping a sitting posture

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Changing posture
Description: Participants will transition from sitting to standing in prescribed hourly intervals. This condition will change posture (sit to stand) while maintaining low energy expenditure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Increasing energy expenditure and changing posture
Description: Participants will transition from sitting to a walking workstation in prescribed hourly intervals. This condition will both increase energy expenditure and change posture.
Study: NCT02047071

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous positive airways pressure
Description: Optimal Continuous positive airways pressure treatment every night plus standard care for OSA consisting of hygienic-dietary advice and lifestyle counseling.
Study: NCT01574001

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Antismoking intervention with no early follow-up
Description: an anti-smoking intervention in line with the 5A's method without early follow-up; follow-up assessment will be limited to two visits: 3 and 12 months after stroke

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Antismoking intervention with minimal early follow-up
Description: Anti-smoking intervention in line with the 5A's method (Ask, Advice, Assess, Assist, Arrange follow-up. The intervention will be carried out 5-7 days after stroke, before the planned discharge from the hospital. Seven days after discharge from a stroke unit a brief telephone/personal advice will be given aimed to motivate patients to quit smoking; follow-up assessment will include two visits: 3 and 12 months after stroke

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Antismoking intervention with intensive early follow-up
Description: an anti-smoking intervention in line with the 5A's method will be given, including four follow-up visits within 6 weeks after discharge from the hospital (week 1, week 2, week 4, week 6 after stroke); follow-up assessment will include two visits: 3 and 12 months after stroke
Study: NCT00213304

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: varicella vaccine (VARIVAX)
Study: NCT03694665

Intervention type: OTHER
Group type: OTHER
Intervention: Lung recruitment maneuver
Description: A Lung recruitment maneuver is aimed to resolve atelectasis during mechanical ventilation. It consists in a brief and controlled increment in airways pressure using pressure control ventilation. Positive end-expiratory pressure (PEEP) is increases every 5 centimeters of water (cmH2O), from 0 to 20 cmH2O keeping a fixed driving pressure of 20 cmH2O. A final step of 40 cmH2O of plateau pressure was maintained for 10 breaths, returning then to standard ventilatory settings.
Study: NCT03613337

Intervention type: OTHER
Intervention: clinical restenosis
Description: The primary endpoints is clinical restenosis, the investigators will compared the incidence of clinical restenosis by different smoking status.
Study: NCT01765478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM71224 single ascending dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM71224 single ascending dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM71224 single ascending dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM71224 single ascending dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM71224 single ascending dose
Study: NCT01352481

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early parent-based speech intervention program
Description: Seven 1h sessions during a three-month period.
Study: NCT01765478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM71224 single ascending dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM71224 food effect

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM71224 food effect

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM71224 Multiple ascending dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM71224 Multiple ascending dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM71224 Multiple ascending dose
Study: NCT00223236

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citicoline
Description: Citicoline or placebo will be given beginning at one table (500mg)/day with an increase to two tablets (1000mg)/day at week 2, three tablets (1500mg)/day at week 4 and four tablets (2000mg)/day at week 6. Patients will remain on 2000mg/day through week 12. Doses will be decreased if needed due to side effects.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching active medication in all other aspects.
Study: NCT02122068

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentalizing Imagery Therapy
Description: 4 week long meditation and mindfulness intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation cd
Study: NCT00835731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: misoprostol
Description: 400mcg misoprostol, buccal administration, 1 time dosing 3-4 hours before abortion by D\&E

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dilapan-S, vitamin B-12
Description: One Dilapan-S rod placed in the cervix 3-4 hours before abortion by D\&E. Control: 1000mcg vitamin B-12, buccal administration 3-4 hours before abortion by D\&E